Back to mobile site

cbdMD reports 19% revenue growth in second quarter

May 14, 2026 4:10 PM EDT

cbdMD Inc. (NYSE American: YCBD) reported net sales of $5.6 million for the second quarter of fiscal 2026, representing a 19% increase compared to $4.7 million in the same period last year. The Charlotte-based CBD company also posted 12% sequential revenue growth from the first quarter of fiscal 2026.

The company recorded a net loss attributable to common shareholders of $876,783, or $0.08 per share, for the quarter ended March 31, 2026. This compared to a net loss of $1.5 million, or $1.90 per share, in the second quarter of fiscal 2025.

cbdMD completed the acquisition of Bluebird Botanicals in mid-January 2026. The acquisition contributed to revenue growth, though integration costs created an earnings impact during the quarter. The company reported that Bluebird began generating positive income in March.

Direct-to-consumer sales totaled $3.8 million, representing 67% of total net sales and a 4% increase from the prior year. Wholesale net sales reached $1.8 million, or 33% of total sales, marking a 65% increase year-over-year.

The company's loss from operations was $801,000 compared to $485,000 in the prior year period. Non-GAAP adjusted EBITDA loss was approximately $220,000 versus $197,000 in the second quarter of fiscal 2025.

cbdMD reported working capital of $5.4 million and cash on hand of $2.6 million as of March 31, 2026, compared to working capital of $3.3 million and cash of $2.2 million at September 30, 2025.

The Centers for Medicare & Medicaid Services activated a pathway for hemp-derived CBD products through the Beneficiary Enhancement Initiative on April 1, 2026. The program allows approved participants to furnish eligible hemp-derived products to beneficiaries at up to $500 annually per eligible beneficiary.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Related Entities

Dividend, Earnings, Definitive Agreement, Maynard Um, Mark Zuckerberg, FDA, ARK